Stereotaxis Inc (STXS)

$2.29 +0.17 (8.02%)
Market Cap 202.18M
Revenue (ttm) 26.92M
Net Income (ttm) -24.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89.34%
Debt to Equity Ratio 0.00
Volume 801,879
Avg Vol 587,536
Day's Range N/A - N/A
Shares Out 91.07M
Stochastic %K 25%
Beta 1.62
Analysts Strong Sell
Price Target $4.25

Company Profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is design...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 314 678 6100
Address:
710 North Tucker Boulevard, Suite 110, Saint Louis, United States
Forenzi
Forenzi Nov. 18 at 10:55 PM
$STXS not a lot of shares though. Would rather have seen the strategic industry partner buy a slug in the open market accompanied by actually divulging its name
1 · Reply
alexpitti
alexpitti Nov. 18 at 9:59 PM
$STXS insider buy
1 · Reply
zbenz
zbenz Nov. 18 at 9:54 PM
$STXS eddie needs a brain ablation
0 · Reply
TonySoprano1987
TonySoprano1987 Nov. 18 at 10:43 AM
$STXS dilution at $2.0 again? Why not at +$3 ...
0 · Reply
Georges8792
Georges8792 Nov. 17 at 6:12 PM
$STXS https://www.linkedin.com/posts/michelle-meyer-b8696b15_another-first-for-overland-park-regional-ugcPost-7396239652749459456-5cpr?utm_medium=ios_app&rcm=ACoAADRx6v4B54eq7jmLG3UwhtnBprtqfVsygQg&utm_source=social_share_send&utm_campaign=share_via
0 · Reply
Eddypgil
Eddypgil Nov. 17 at 3:23 PM
$STXS I think a lot of the selling is tax loss selling. Plus many anticipate a secondary for $10 M in coming months.
0 · Reply
TonySoprano1987
TonySoprano1987 Nov. 17 at 3:15 PM
$STXS sub $2 !
0 · Reply
alexpitti
alexpitti Nov. 15 at 3:05 AM
$STXS we are so back
2 · Reply
alexpitti
alexpitti Nov. 14 at 4:29 AM
$STXS seems like every stock crashed on earnings this season. Not even sure why we fell 20%. We got FDA approval of GenesisX and are done with the modules for FDA approval of MAGiC. That's what we wanted. Small deviations in sales of a few hundred thousand are irrelevant when we look at the next 2 years.
3 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 7:22 PM
$STXS secures FDA clearance for GenesisX — what’s the impact? 🚀 The new system breaks down infrastructure barriers, making it easier for hospitals to adopt and potentially boosting STXS's long-term growth. Following the announcement, shares traded flat, but year-to-date, they are up 6.6%, outpacing the industry's 4.1% growth. Explore the full potential here 👉 https://www.zacks.com/stock/news/2790857/stxs-secures-fda-approval-for-genesisx-to-broaden-surgical-robotics?cid=sm-stocktwits-2-2790857-body-20999&ADID=SYND_STOCKTWITS_TWEET_2_2790857_BODY_20999
0 · Reply
Latest News on STXS
Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 7:51 PM EST - 7 days ago

Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript

Stereotaxis Reports 2025 Third Quarter Financial Results

Nov 11, 2025, 4:01 PM EST - 7 days ago

Stereotaxis Reports 2025 Third Quarter Financial Results

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance

Nov 10, 2025, 4:05 PM EST - 8 days ago

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

Oct 21, 2025, 9:00 AM EDT - 4 weeks ago

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs

Oct 15, 2025, 7:32 AM EDT - 4 weeks ago

Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs

Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias

Oct 13, 2025, 7:34 AM EDT - 5 weeks ago

Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias

Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System

Sep 22, 2025, 7:56 AM EDT - 2 months ago

Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System

First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

Sep 2, 2025, 8:08 AM EDT - 2 months ago

First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

Stereotaxis to Present at Upcoming Investor Conferences

Sep 2, 2025, 7:51 AM EDT - 2 months ago

Stereotaxis to Present at Upcoming Investor Conferences

Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

Aug 28, 2025, 7:47 AM EDT - 2 months ago

Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 1:24 PM EDT - 3 months ago

Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript

Stereotaxis Reports 2025 Second Quarter Financial Results

Aug 7, 2025, 4:01 PM EDT - 3 months ago

Stereotaxis Reports 2025 Second Quarter Financial Results

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

Jul 28, 2025, 7:48 AM EDT - 4 months ago

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 23, 2025, 8:00 AM EDT - 4 months ago

Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

Jul 17, 2025, 8:32 AM EDT - 4 months ago

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

Stereotaxis: Recurring Revenue Inflection

Jul 6, 2025, 2:13 AM EDT - 4 months ago

Stereotaxis: Recurring Revenue Inflection

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

Jul 1, 2025, 9:00 AM EDT - 5 months ago

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript

May 12, 2025, 7:04 PM EDT - 6 months ago

Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript

Stereotaxis Reports 2025 First Quarter Financial Results

May 12, 2025, 4:01 PM EDT - 6 months ago

Stereotaxis Reports 2025 First Quarter Financial Results

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 22, 2025, 7:00 AM EDT - 7 months ago

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

Apr 21, 2025, 8:00 AM EDT - 7 months ago

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

Mar 19, 2025, 8:01 AM EDT - 8 months ago

Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

Stereotaxis to Present at 37th Annual Roth Conference

Mar 10, 2025, 8:02 AM EDT - 9 months ago

Stereotaxis to Present at 37th Annual Roth Conference

Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn

Mar 7, 2025, 9:10 AM EST - 9 months ago

Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn

Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 10:34 AM EST - 9 months ago

Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript

Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

Mar 3, 2025, 7:32 AM EST - 9 months ago

Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance

Mar 3, 2025, 7:31 AM EST - 9 months ago

Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance

Stereotaxis Reports 2024 Full Year Financial Results

Mar 3, 2025, 7:30 AM EST - 9 months ago

Stereotaxis Reports 2024 Full Year Financial Results

Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference

Feb 25, 2025, 8:03 AM EST - 9 months ago

Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference

Stock Market Sleeps On Stereotaxis MAGiC CE Mark

Feb 14, 2025, 10:41 AM EST - 9 months ago

Stock Market Sleeps On Stereotaxis MAGiC CE Mark

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Feb 3, 2025, 4:05 PM EST - 10 months ago

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Stereotaxis Announces First GenesisX Robotic System Order

Jan 30, 2025, 8:09 AM EST - 10 months ago

Stereotaxis Announces First GenesisX Robotic System Order

Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter

Jan 27, 2025, 8:00 AM EST - 10 months ago

Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter

Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology

Jan 14, 2025, 7:21 AM EST - 11 months ago

Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology

Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA

Dec 9, 2024, 7:25 AM EST - 1 year ago

Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA

Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems

Dec 2, 2024, 8:45 AM EST - 1 year ago

Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems

Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025

Dec 2, 2024, 5:03 AM EST - 1 year ago

Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025

Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 8:28 AM EST - 1 year ago

Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference

Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

Nov 25, 2024, 8:21 AM EST - 1 year ago

Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

Nov 20, 2024, 8:18 AM EST - 1 year ago

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 7:03 PM EST - 1 year ago

Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript

Stereotaxis Reports 2024 Third Quarter Financial Results

Nov 11, 2024, 4:02 PM EST - 1 year ago

Stereotaxis Reports 2024 Third Quarter Financial Results

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

Oct 21, 2024, 8:41 AM EDT - 1 year ago

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress

Sep 3, 2024, 8:53 AM EDT - 1 year ago

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society's HRX Congress

Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval

Aug 25, 2024, 7:22 PM EDT - 1 year ago

Stereotaxis Receives CE Mark For GenesisX, Nears MAGiC Approval

Stereotaxis, Inc. (STXS) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 11:33 PM EDT - 1 year ago

Stereotaxis, Inc. (STXS) Q2 2024 Earnings Call Transcript

Stereotaxis Reports 2024 Second Quarter Financial Results

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Stereotaxis Reports 2024 Second Quarter Financial Results

Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX

Aug 12, 2024, 4:03 PM EDT - 1 year ago

Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX

Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024

Jul 22, 2024, 4:05 PM EDT - 1 year ago

Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024

Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

Jul 18, 2024, 4:13 PM EDT - 1 year ago

Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

Forenzi
Forenzi Nov. 18 at 10:55 PM
$STXS not a lot of shares though. Would rather have seen the strategic industry partner buy a slug in the open market accompanied by actually divulging its name
1 · Reply
alexpitti
alexpitti Nov. 18 at 9:59 PM
$STXS insider buy
1 · Reply
zbenz
zbenz Nov. 18 at 9:54 PM
$STXS eddie needs a brain ablation
0 · Reply
TonySoprano1987
TonySoprano1987 Nov. 18 at 10:43 AM
$STXS dilution at $2.0 again? Why not at +$3 ...
0 · Reply
Georges8792
Georges8792 Nov. 17 at 6:12 PM
$STXS https://www.linkedin.com/posts/michelle-meyer-b8696b15_another-first-for-overland-park-regional-ugcPost-7396239652749459456-5cpr?utm_medium=ios_app&rcm=ACoAADRx6v4B54eq7jmLG3UwhtnBprtqfVsygQg&utm_source=social_share_send&utm_campaign=share_via
0 · Reply
Eddypgil
Eddypgil Nov. 17 at 3:23 PM
$STXS I think a lot of the selling is tax loss selling. Plus many anticipate a secondary for $10 M in coming months.
0 · Reply
TonySoprano1987
TonySoprano1987 Nov. 17 at 3:15 PM
$STXS sub $2 !
0 · Reply
alexpitti
alexpitti Nov. 15 at 3:05 AM
$STXS we are so back
2 · Reply
alexpitti
alexpitti Nov. 14 at 4:29 AM
$STXS seems like every stock crashed on earnings this season. Not even sure why we fell 20%. We got FDA approval of GenesisX and are done with the modules for FDA approval of MAGiC. That's what we wanted. Small deviations in sales of a few hundred thousand are irrelevant when we look at the next 2 years.
3 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 7:22 PM
$STXS secures FDA clearance for GenesisX — what’s the impact? 🚀 The new system breaks down infrastructure barriers, making it easier for hospitals to adopt and potentially boosting STXS's long-term growth. Following the announcement, shares traded flat, but year-to-date, they are up 6.6%, outpacing the industry's 4.1% growth. Explore the full potential here 👉 https://www.zacks.com/stock/news/2790857/stxs-secures-fda-approval-for-genesisx-to-broaden-surgical-robotics?cid=sm-stocktwits-2-2790857-body-20999&ADID=SYND_STOCKTWITS_TWEET_2_2790857_BODY_20999
0 · Reply
DomLuminous
DomLuminous Nov. 13 at 6:54 PM
$STXS what a crash, but the whole markets are selling off. This never went euphoric.
0 · Reply
ZacksResearch
ZacksResearch Nov. 13 at 6:22 PM
$STXS just scored FDA approval — game-changer for surgical robotics? 🤖 GenesisX, its newly cleared robotic system, is designed to boost hospital adoption and accelerate growth across the platform. See why this approval could be a major catalyst 👉 https://www.zacks.com/stock/news/2790857/stxs-secures-fda-approval-for-genesisx-to-broaden-surgical-robotics?cid=sm-stocktwits-2-2790857-teaser-20986&ADID=SYND_STOCKTWITS_TWEET_2_2790857_TEASER_20986
0 · Reply
_Not_Sure_
_Not_Sure_ Nov. 13 at 4:49 PM
$STXS Please remind me @alexpitti if they FDA approval you referred to in another post today is expected to be delayed or not to be delayed by the shutdown. (Not that these approvals wouldn’t be delayed under normal circumstances anyway)
1 · Reply
TonySoprano1987
TonySoprano1987 Nov. 13 at 12:43 PM
$STXS sub $2 possible in next weeks?
1 · Reply
laguna2
laguna2 Nov. 12 at 6:48 PM
$STXS RE CC. Pretty good progress overall. Didn't know they had 15 Genesis systems backlogged. Magic Sweep adoption is encouraging and bodes well for razor blade model once Magic gets FDA cleared. Guidance really a floor but answers in Q&A wrt systems share of revenues implies sig upside. First mention of instances where PCI systems in center(s) that aren't current EP customers. Stock can fill gaps while waiting for Magic clearance.
4 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 5:45 PM
Roth Capital updates rating for Stereotaxis ( $STXS ) to Buy, target set at 4.
0 · Reply
alexpitti
alexpitti Nov. 12 at 3:42 PM
Updated timelines $STXS
2 · Reply
cheating_stock_investor
cheating_stock_investor Nov. 12 at 3:17 PM
$STXS im thinking one delay fda is waiting to hear on magic is the 90 day results from the patients as well as 180 day results. Already based on what i gathetered the non reoccurence of arythmias are above existing ablation therapies and are proven to be superior at 84%. Acute is at 94% so theres no doubt that this shouldnt get approved. It seems fda just wants to err on the cautious side. I still think had there not been a shutdown we could have met the 2025 end of year approval deadline.
2 · Reply
DomLuminous
DomLuminous Nov. 12 at 3:14 PM
$STXS more pain. Potential shake out before news hits?
0 · Reply
Daquanladariusblackman2
Daquanladariusblackman2 Nov. 12 at 2:47 PM
$STXS down almost 20% eddy? OUUCCCHHH! I thought it would open in the $2.70s @Eddypgil
1 · Reply
Daquanladariusblackman2
Daquanladariusblackman2 Nov. 12 at 2:46 PM
$STXS @Eddypgil right now
0 · Reply
Daquanladariusblackman2
Daquanladariusblackman2 Nov. 12 at 2:45 PM
$STXS 😱😱😱 @Eddypgil
0 · Reply